Black patients show inferior survival despite similar cytogenetics and treatment response

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses

Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG

The hidden biology of addiction and cancer

Independent clones in CLL show oligoclonality and early evolution patterns

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies